Blog
RSS FeedPosted by Michael Wonder on 09 May 2022
The Center for Medicare and Medicaid Innovation - toward value based care
9 May 2022 - Before the enactment of the Patient Protection and Affordable Care Act in 2010, experimentation with Medicare or ...
Posted by Michael Wonder on 08 May 2022
Supporting innovation in Medicaid policy - interventions to increase adoption of RCTs
7 May 2022 - Randomised, controlled trials remain underutilised within the Medicaid program, even though state Medicaid programs regularly implement new ...
Posted by Michael Wonder on 18 Apr 2022
Risks to the 340B drug pricing program related to manufacturer restrictions on drug availability
15 April 2022 - On 21 March 2022, Johnson & Johnson became the 16th pharmaceutical manufacturer to restrict the delivery of ...
Posted by Michael Wonder on 17 Oct 2021
Recent trends in Medicaid spending and use of drugs with US Food and Drug Administration accelerated approval
8 October 2021 - In this cross-sectional study of 216 drugs granted accelerated approval from 1992 through 2020, relative to all ...
Posted by Michael Wonder on 21 Jun 2021
Health equity and Medicaid transformation — operationalising President Biden’s agenda
19 June 2021 - President Biden has made reforms intended to “protect and strengthen Medicaid” a centrepiece of his health policy ...
Posted by Michael Wonder on 28 Oct 2020
Medicare and Medicaid to cover early COVID-19 vaccine
26 October 2020 - The new regulations would allow beneficiaries to receive a vaccine under “emergency authorisation” at no cost. ...
Posted by Michael Wonder on 12 Aug 2020
CMS proposes changes to Medicaid best price rule: a potential boost to value-based contracting
9 August 2020 - For well over a decade policymakers have declared the healthcare system is moving towards value-based pricing ...
Posted by Michael Wonder on 22 Jun 2020
Trump Administration proposes Medicaid reforms to encourage innovative contracting models
22 June 2020 - On Wednesday, June 17, the Centers for Medicare and Medicaid Services proposed a series of reforms ...
Posted by Michael Wonder on 02 Jun 2020
Estimating the cost of delayed generic drug entry to Medicaid
1 June 2020 - Delays in market entry of generic drugs are common. ...
Posted by Michael Wonder on 04 Apr 2020
Alternative drug purchasing arrangements do not justify raising the prices Medicaid pays for brand drugs
3 April 2020 - As the prescription drug pipeline fills with very high-cost gene therapies and specialty drugs, affordability and access ...
Posted by Michael Wonder on 01 Feb 2020
Trump’s Medicaid changes offer states new powers to lower drug costs — with a catch
31 January 2020 - The Trump administration on Thursday unveiled a powerful new tool for states to rein in prescription ...
Posted by Michael Wonder on 17 Oct 2019
Most state Medicaid programs continue to restrict access to hepatitis C medicines
16 October 2019 - Despite guidance from the federal government, most state Medicaid programs continue to deny hepatitis C treatments ...
Posted by Michael Wonder on 26 Jun 2019
CMS approves Louisiana State Plan Amendment for supplemental rebate agreements using a modified subscription model for hepatitis C therapies in Medicaid
26 June 2019 - State Plan Amendment permits Louisiana to negotiate supplemental drug rebates to assist the state in controlling expenditures ...
Posted by Michael Wonder on 22 May 2019
Extending VBP models into Medicaid drug purchasing: challenges and opportunities
22 May 2019 - Over the past decade, both public and private payers have increasingly sought to develop payment policies that ...
Posted by Michael Wonder on 08 Apr 2019
Pazdur on pandemonium: calls for collaboration, competition on PD-1 drugs
8 April 2019 - Pazdur chastises PD-1/PD-L1 pharmas for losing sight of patients. ...